Literature DB >> 2714067

Antibiotics for penetrating abdominal trauma: a prospective comparative trial of single agent cephalosporin therapy versus combination therapy.

B A Bivins1, L Crots, F N Obeid, V J Sorensen, H M Horst, J J Fath.   

Abstract

In this prospective, comparative study, 129 patients who sustained penetrating abdominal trauma were randomized to receive preoperatively, and for 3-5 days postoperatively, one of three antibiotic regimens: Group I--cefotaxime (CTX) (2 Gm Q8H), Group II--cefoxitin (2 Gm Q6H), or Group III--clindamycin (900 mg Q8H) and gentamicin (3-5 mg/kg/day in divided doses Q8H). The three groups were similar in terms of the following: age, sex, severity of injury, number of organs injured, colon injuries, shock, blood transfusions, or positive intraoperative cultures. Septic complications occurred as follows: Group I--6.9%, Group II--2.3%, and Group III--6.9%. The three regimens ranked as follows in terms of therapy costs: CTX less than cefoxitin less than clindamycin and gentamicin. It is concluded that single agent therapy with a cephalosporin is preferable to combination therapy on the basis of equivalent effectiveness, lower toxicity, and lower costs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714067     DOI: 10.1016/0732-8893(89)90055-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Cephalosporins--cefotaxime 10 years later, a major drug with continued use.

Authors:  H C Neu
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Prophylactic antibiotics for penetrating abdominal trauma: duration of use and antibiotic choice.

Authors:  Philip J Herrod; Hannah Boyd-Carson; Brett Doleman; James Blackwell; John P Williams; Ashish Bhalla; Richard L Nelson; Samson Tou; Jon N Lund
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.